Updates in Splenic and Nodal Marginal Zone Lymphoma

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

American Society for Transplantation and Cellular Therapy

June 2nd 2025

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Researchers conducted a prospective, multicenter phase II clinical trial demonstrating that prolonged administration of ruxolitinib after allogeneic HCT is associated with notably low rates of cGVHD.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

May 5th 2025

Glofitamab Combo Boosts Survival vs Rituximab in Relapsed/Refractory DLBCL

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Roman Fabbricatore

Sintilimab/Chidamide Combo Shows Activity in Early-Stage ENKTL

The safety profile for glofitamab plus gemcitabine and oxaliplatin in diffuse large B-cell lymphoma was consistent with known risks for individual drugs.

At a median follow-up of 17.0 months, the sintilimab/chidamide regimen elicited 1-year PFS and OS rates of 95.7% and 95.3%, respectively.

Ashley Chan

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

At a median follow-up of 17.0 months, the sintilimab/chidamide regimen elicited 1-year PFS and OS rates of 95.7% and 95.3%, respectively.

Related Content

Tim Cortese

June 3rd 2025

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

American Society for Transplantation and Cellular Therapy

June 2nd 2025

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Researchers conducted a prospective, multicenter phase II clinical trial demonstrating that prolonged administration of ruxolitinib after allogeneic HCT is associated with notably low rates of cGVHD.

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

May 5th 2025

Glofitamab Combo Boosts Survival vs Rituximab in Relapsed/Refractory DLBCL

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Roman Fabbricatore

Sintilimab/Chidamide Combo Shows Activity in Early-Stage ENKTL

The safety profile for glofitamab plus gemcitabine and oxaliplatin in diffuse large B-cell lymphoma was consistent with known risks for individual drugs.

Ashley Chan